Meng Li

Biography
Dr. Meng Li is a physician-scientist by training. He brings a rare combination of scientific depth and clinical development leadership, with more than a decade of experience advancing early- and late-stage oncology programs across the pharmaceutical industry. He is widely recognized for his contributions to cancer genomics, liquid biopsy, and novel therapeutics. His research has contributed to the discovery of multiple human cancer genes, including ARID1A, ARID2, MLL2, MLL3, and BCORL1. He is also an inventor of BEAMing technology, which leverages circulating tumor DNA for cancer detection, disease stratification, and monitoring of treatment response. His work has helped shape modern oncology practice, and he has published as a lead author in prestigious journals, including Science, Nature Genetics, Nature Medicine, Nature Biotechnology, Nature Methods, and Blood. He has also been a driving force in targeting epigenetic machinery and advancing novel immunotherapies for the treatment of human cancer.

---

Talk
Targeting Epigenetics for Cancer Diagnosis and Treatment
Prifetrastat is a novel, selective catalytic inhibitor of KAT6A&B. In a phase 1/2 trial, prifetrastat in combination with fulvestrant demonstrated promising antitumor activity and an acceptable safety profile in patients with HR-positive, HER2-negative metastatic breast cancer These findings establish KAT6A&B as druggable cancer targets, provide clinical proof of concept, and reveal a new therapeutic avenue.

Emerging Therapeutics Showcase:
Pfizer
Pfizer is an american multinational pharmaceutical and biotechnology corporation. Pfizer develops medicine and vaccines for immunology, oncology and general medicine.